These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10367678)

  • 1. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.
    Ryan AM; Eppler DB; Hagler KE; Bruner RH; Thomford PJ; Hall RL; Shopp GM; O'Neill CA
    Toxicol Pathol; 1999; 27(1):78-86. PubMed ID: 10367678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
    Margolin K; Gordon MS; Holmgren E; Gaudreault J; Novotny W; Fyfe G; Adelman D; Stalter S; Breed J
    J Clin Oncol; 2001 Feb; 19(3):851-6. PubMed ID: 11157039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
    Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
    Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
    Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
    J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.
    Sweeney CJ; Miller KD; Sissons SE; Nozaki S; Heilman DK; Shen J; Sledge GW
    Cancer Res; 2001 Apr; 61(8):3369-72. PubMed ID: 11309294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
    Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
    J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
    Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
    Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
    Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
    J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey.
    Zimmermann RC; Xiao E; Husami N; Sauer MV; Lobo R; Kitajewski J; Ferin M
    J Clin Endocrinol Metab; 2001 Feb; 86(2):768-72. PubMed ID: 11158044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
    Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
    Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor and vascular targeting of solid tumors.
    Brekken RA; Thorpe PE
    Anticancer Res; 2001; 21(6B):4221-9. PubMed ID: 11908675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies.
    Kim KJ; Li B; Houck K; Winer J; Ferrara N
    Growth Factors; 1992; 7(1):53-64. PubMed ID: 1380254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
    Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
    Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation.
    Gerber HP; Vu TH; Ryan AM; Kowalski J; Werb Z; Ferrara N
    Nat Med; 1999 Jun; 5(6):623-8. PubMed ID: 10371499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
    Lee CG; Heijn M; di Tomaso E; Griffon-Etienne G; Ancukiewicz M; Koike C; Park KR; Ferrara N; Jain RK; Suit HD; Boucher Y
    Cancer Res; 2000 Oct; 60(19):5565-70. PubMed ID: 11034104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.